Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study

Chunfang Hao; Xu Wang; Yehui Shi; Zhongsheng Tong; Shufen Li; Xiaodong Liu; Lan Zhang; Jie Zhang; Wenjing Meng; Li Zhang

doi:10.4143/crt.2024.340

Articles

Page Path: HOME > Cancer Res Treat > Volume 57(2); 2025 > Article

Original Article Breast cancer Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study: Chunfang Hao^1,2,3,, Xu Wang^1,2, Yehui Shi^1,2, Zhongsheng Tong^1,2, Shufen Li^1,2, Xiaodong Liu^1,2, Lan Zhang^1,2, Jie Zhang³, Wenjing Meng^1,2, Li Zhang^1,2; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2025;57(2):434-442.
DOI: https://doi.org/10.4143/crt.2024.340
Published online: August 9, 2024

¹Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

²National Clinical Research Center for Cancer, Tianjin, China

³Department of Breast Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China

Correspondence: Chunfang Hao, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Rd, Ti Yuan Bei, Hexi District, Tianjin 300060, China
Tel: 86-13602031629 Fax: 86-22-23359337 E-mail: haochunfang@tjmuch.com

*Chunfang Hao and Xu Wang contributed equally to this work.

• Received: April 3, 2024 • Accepted: August 8, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,481 Views
129 Download
1 Web of Science
1 Crossref
1 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Approximately 50%-74% of patients with metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer do not respond to trastuzumab, with 75% of treated patients experiencing disease progression within a year. The combination of pyrotinib and capecitabine has showed efficacy in these patients. This study evaluates the efficacy and safety of pyrotinib combined with metronomic vinorelbine for trastuzumab-pretreated HER2-positive advanced breast cancer patients.
Materials and Methods
In this phase 2 trial, patients aged 18-75 years with HER2-positive advanced breast cancer who had previously failed trastuzumab treatment were enrolled to receive pyrotinib 400 mg daily in combination with vinorelbine 40mg thrice weekly. The primary endpoint was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results
From October 21, 2019, to January 21, 2022, 36 patients were enrolled and received at least one dose of study treatment. At the cutoff date, 20 experienced disease progression or death. With a median follow-up duration of 35 months, the median PFS was 13.5 months (95% confidence interval [CI], 8.3 to 18.5). With all patients evaluated, an ORR of 38.9% (95% CI, 23.1 to 56.5) and a DCR of 83.3% (95% CI, 67.2 to 93.6) were achieved. The median OS was not reached. Grade 3 adverse events (AEs) were observed in 17 patients, with diarrhea being the most common (27.8%), followed by vomiting (8.3%) and stomachache (5.6%). There were no grade 4/5 AEs.
Conclusion
Pyrotinib combined with metronomic vinorelbine showed promising efficacy and an acceptable safety profile in HER2-positive advanced breast cancer patients after trastuzumab failure.
Key words: Pyrotinib, Metronomic vinorelbine, Trastuzumab resistance, Advanced breast cancer

Introduction

Breast cancer prevails as the primary malignancy among Chinese women, especially in urban areas, with a rising incidence. Human epidermal growth factor receptor 2 (HER2)–positive breast cancer, characterized by the overexpression of the HER2 protein due to gene amplification, is notably aggressive and associated with a poorer prognosis compared to other subtypes. Approximately 20%-30% of breast cancer patients in China exhibit HER2 gene amplification/overexpression [1,2].

Trastuzumab emerges as a cornerstone therapeutic agent for HER2-positive breast cancer. The combination of pertuzumab, trastuzumab, and taxane serves as the standard first-line treatment while other trastuzumab-based therapies are recommended in third- or later-line settings [3]. However, pertuzumab was approved in China only recently, and its high-cost limits accessibility for many Chinese patients. Consequently, few patients in China have received pertuzumab treatment. In contrast, trastuzumab has been widely used in both early and metastatic settings, making trastuzumab resistance a significant challenge in the management of HER2-positive breast cancer [4].

Unlike trastuzumab, which binds to the extracellular domain of HER2, small-molecule tyrosine kinase inhibitor (TKI) targets the intracellular tyrosine kinase domain, inhibiting HER2 signaling even with extracellular domain alterations in trastuzumab-resistant patients [5]. Furthermore, pan-HER TKI enhances antitumor activity by inhibition of multiple HER family members, including epidermal growth factor receptor (EGFR), HER2, and HER3 [6-8]. Pyrotinib is an indigenous pan-HER TKI developed in China that gained rapid national approval in September 2018 for HER2-positive metastatic breast cancer [9]. Phase III PHENIX and PHOEBE studies validated the efficacy of pyrotinib in combination with capecitabine for trastuzumab-pretreated patients with advanced breast cancer with improvements in both progression-free survival (PFS) and overall survival (OS), thereby establishing the combination of pyrotinib and capecitabine as a preferred treatment option following trastuzumab resistance [10-12]. However, this combination was presented with notable gastrointestinal adverse events (AEs), particularly diarrhea, which was both the most common and severe AE. Over 30% of patients experienced grade ≥ 3 diarrhea, even with primary prophylaxis using loperamide [13-15]. Other chemotherapy drug, such as docetaxel, also had a high incidence of grade ≥ 3 diarrhea, when co-administrated with pyrotinib and trastuzumab [16,17]. Therefore, there is a need to identify alternative chemotherapy options with reduced gastrointestinal toxicity. Vinorelbine is a semi-synthetic vinca alkaloid that exerts its action on tubulin, effectively disrupting the formation of mitotic spindles essential for cell division. This mechanism confers its potent anti-proliferative effects [18]. A phase II study demonstrated that intravenous vinorelbine combined with trastuzumab and lapatinib were effective and safe in metastatic HER2-positive breast cancer patients [19]. Previous retrospective studies showed promising effects of pyrotinib plus oral vinorelbine in HER2-positive metastatic breast cancer patients pretreated with trastuzumab and taxane [20,21]. Vinorelbine can be administrated both orally and intravenously. Jiang et al. [22] phase II trial reported no significant difference between these two administration routes, but oral vinorelbine was associated with more gastrointestinal AEs and less myelosuppression. For the sake of convenience and economic factor, oral vinorelbine was selected. To reduce gastrointestinal toxicity, metronomic vinorelbine is administered at low doses. Metronomic vinorelbine demonstrated its good tolerance, even among elderly patients [23,24]. Moreover, metronomic vinorelbine was found to possess antiangiogenic, immunomodulatory, and cancer stem cell-targeting effects, rather than depending solely on the cytotoxicity of the maximum tolerated dose [25], which may provide synergistic effect when combined with other antitumor drugs. A phase I-A dose-escalation study has confirmed the safe administration of metronomic vinorelbine up to 50 mg thrice weekly, demonstrating sustained antitumor efficacy without significant toxicities or drug accumulation [26]. This study aims to explore the efficacy and safety of a novel dual oral regimen, combining pyrotinib with metronomic vinorelbine chemotherapy, for the treatment of HER2-positive advanced breast cancer patients who failed the trastuzumab therapy.

Materials and Methods

1. Study design and patients

This investigator-initiated, single-center, single-arm, open-label prospective phase II trial (NCT04903652) enrolled female patients aged 18 to 75, with histologically confirmed HER2-positive (defined by an immunohistochemistry score of 3+ and/or a positive fluorescence in situ hybridization test, as confirmed by investigators) recurrent/metastatic breast cancer who experienced disease progression (PD) during or after trastuzumab treatment (discontinued < 12 months prior) from the Tianjin Medical University Cancer Institute and Hospital. Eligibility criteria included an Eastern Cooperative Oncology Group performance status score of 0-2, an expected overall survival of ≥ 12 weeks, at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 and normal major organ function. Exclusion criteria comprised visceral crisis, conditions impacting oral medication intake or absorption, prior treatments for advanced/metastatic disease including radiotherapy, endocrine therapy, surgery (except local puncture), or targeted therapy. Other malignancies within 5 years, and current pregnancy or breastfeeding also led to exclusion.

2. Procedures

Eligible patients received oral pyrotinib 400 mg once daily and oral vinorelbine 40 mg three time a week for each 21-day cycle. Treatment was continued until PD, intolerable toxicity, or withdrawal of consent.

Every 8 weeks, patients underwent evaluation of tumor response via advanced computed tomography or magnetic resonance imaging, until PD or death, following RECIST ver. 1.1 guidelines. During the study, AEs were graded based on the National Cancer Institute Common Terminology Criteria for Adverse Events ver. 4.03.

Dose adjustments or delays were based on the highest grade of hematologic or non-hematologic toxicities observed in patients. Any treatment delay due to AEs shouldn’t exceed 3 weeks, with the subsequent chemotherapy cycle adjusted accordingly. Doses can be modified in response to various conditions such as specific absolute neutrophil count counts, febrile neutropenia, platelet levels, and durations of anemia or neurotoxicity. If a patient develops severe neutropenia in a treatment cycle, the drug dosage may be reduced for subsequent cycle. Each drug has a maximum allowance dose reduction limit; exceeding this limit may necessitate the patient’s withdrawal from the study. Once a dose is decreased, it should be consistently maintained in the following administrations.

3. Endpoints

The primary endpoint was PFS, defined as the period from the initiation of study treatment to either the first instance of PD or death from any cause. Secondary endpoints included the objective response rate (ORR), characterized as the ratio of patients achieving confirmed complete response (CR) or partial response (PR) as the best overall response, duration of response (time from first CR or PR to PD for patients with confirmed objective response), disease control rate (DCR) involving CR, PR, or stable disease, OS, and safety.

4. Statistical analysis

Drawing from the EMILIA study, the median PFS of the combined treatment of lapatinib and capecitabine was 6.4 months [27]. The goal of the study treatment was to extend the median PFS to 12.0 months. Assuming survival times follow an exponential distribution with a two-sided test at a significance level of 0.05, considering a 1-year enrollment period followed by a 1-year follow-up, the study aimed to attain a statistical power of 80% with a requirement of 20 observed events. Based on these considerations, the required sample size was calculated to be 32 patients. Accounting for a 10% potential dropout rate, the target sample size was set at 36 patients.

Efficacy and safety were assessed in all patients who received at least one dose of the study drug. Continuous variables were presented as median (range), while categorical variables were expressed as frequency (%). The 95% confidence intervals (CIs) for ORR and DCR were calculated using the Clopper-Pearson method. Median PFS and OS were estimated via the Kaplan-Meier method, with 95% CIs calculated using the Brookmeyer-Crowley method. Subgroup comparisons for PFS were conducted using the Cox proportional hazard regression model. For subgroup analysis, primary resistance to trastuzumab was defined as PD at the first radiological reassessment (typically conducted 8-12 weeks or within 3 months after initiating first-line trastuzumab with or without chemotherapy in the metastatic setting) or new recurrences diagnosed during or within 12 months after completing adjuvant trastuzumab treatment. Secondary resistance was defined as PD occurring after two or more lines of trastuzumab-containing regimens that initially achieved disease response or stabilization at the first radiological assessment [28]. All statistical analyses were performed by SAS ver. 9.4 (SAS Institute Inc.). A two-sided p-value of < 0.05 was deemed statistically significant.

Results

1. Patient characteristics

From October 21, 2019, to January 21, 2022, a total of 36 patients were prospectively enrolled. Baseline characteristics are presented in Table 1. All patients received at least one dose of study treatment and were included in the analysis of efficacy and safety. Of these patients, 19 (52.8%) had hormone receptor-positive disease, 23 (63.9%) had multifocal metastasis and 27 (75%) demonstrated hepatic metastatic involvement. Prior to study initiation, 23 (63.9%) had undergone trastuzumab treatment in advanced stage, and nine (25.0%) exhibited primary trastuzumab resistance. Additionally, 15 patients (41.7%) had been previously treated with lapatinib, and eight patients (22.2%) had received chemotherapy in three or more sequential lines.

As of the data cutoff date on December 28, 2023, of 36 patients, 29 experienced PD or mortality, two lost follow-up, and five were still under the study treatment. With a median follow-up duration of 35 months, the median PFS was 13.5 months (95% CI, 8.33 to 18.5) (Fig. 1A). A total of 12 deaths were reported, and the OS data are currently immature. No patient achieved CR while 14 patients obtained PR, yielding an ORR of 38.9% (95% CI, 23.1 to 56.5), with a DCR of 83.3% (95% CI, 67.2 to 93.6).

The post-hoc subgroup analysis results are presented in Table 2. Notably, patients with lung metastases demonstrated a median PFS of 14.2 months, compared to 7.6 months for those without lung metastases (nominal p=0.037) (Fig. 1B). A median PFS of 19.7 months was observed in patients with primary resistance to trastuzumab, versus the secondary resistant population with a median PFS of 10.9 months (nominal p=0.207) (Fig. 1C). All patients underwent prior trastuzumab treatment. For patients who received trastuzumab treatment in the advanced stage, the median PFS reached 13.9 months; while those treated with trastuzumab in the early stage exhibited a median PFS of 11.8 months. And for the population with previous trastuzumab treatment in both advanced and early stages, the median PFS was 13.6 months (Fig. 1D). Of particular significance is that patients with prior treatment of lapatinib had a median PFS of 8.3 months, substantially shorter than the 15.3 months observed in lapatinib-naïve patients (nominal p=0.008) (Fig. 1E).

2. Safety

The most common treatment-related AEs of any grade were diarrhea (94.4%), decreased appetite (88.9%), and nausea (80.6%). Grade 3 AEs were observed in 17 patients, with diarrhea being the most common (10 patients, 27.8%), followed by vomiting (3 patients, 8.3%) and stomachache (2 patients, 5.6%). There were no grade 4/5 AEs (Table 3). No death due to AEs was reported. No new or unexpected AE was identified, and all AEs were manageable.

Discussion

Anti-HER2 antibody-drug conjugates (ADCs) are currently the preferred regimen for patients previously treated with trastuzumab. The EMILIA study established the role of trastuzumab emtansine (T-DM1) in this population, showing a median PFS of 9.6 months and a median OS of 30.9 months [27]. Recently, trastuzumab deruxtecan (T-DXd) achieved amazing outcomes from the phase 3 DESTINY-Breast 03 study with a median PFS of 28.8 months (hazard ratio, 0.33; p < 0.0001) [29]. Both ADCs have been recommended as standard second and third lines of treatment by the National Comprehensive Cancer Network and European Society of Medical Oncology guidelines [3,30]. T-DM1 and T-DXd granted their approval in China in 2020 and 2023, respectively. However, their use was not yet common practice due to economic factors. As such, exploration of small molecule combination therapies is still necessary.

Pyrotinib is an oral, irreversible pan-HER TKI that irreversibly binds to EGFR, HER2, and HER4, thereby preventing downstream signaling and suppressing the growth and survival of tumor cells [31]. Data from a nationwide, prospective, real-world observational study showed that patients who received pyrotinib as a second-line therapy experienced a median PFS of 12.0 months, while those receiving it as a third or subsequent line of therapy had a median PFS of 6.4 months [32]. In the Phase III PHENIX trial, pyrotinib in combination with capecitabine achieved a median PFS of 11.1 months for trastuzumab-treated HER2-positive metastatic breast cancer [12]. Similarly, in the Phase III PHOEBE trial, this combination obtained a median PFS of 12.5 months in HER2-positive metastatic breast cancer, reducing the risk of disease progression or death by 61% compared to lapatinib combined with capecitabine [11]. In this phase II trial, the combination of pyrotinib and metronomic vinorelbine showed promising efficacy with a median PFS 13.5 (95% CI, 8.1 to 20.3) and a DCR of 83.3% (95% CI, 67.2 to 93.6) in HER2-positive advanced breast cancer after trastuzumab failure, exceeding the median PFS of EMILIA study [27], consistent with that of PHOEBE study [11].

The potential of pyrotinib to overcome trastuzumab resistance may explain the promising outcome in trastuzumab-treated HER2-positive breast cancer patients. There are several mechanisms, including the presence of HER2 carboxy-terminal fragment p95HER2 [33], HER2Δ16 variant lacking exon 16 [34], activation of alternative signaling pathways such as phosphoinositide 3-kinase/AKT/mammalian target of rapamycin and mitogen-activated protein kinase [35,36], overexpression of insulin-like growth factor-1 receptor, and amplification of EGFR or HER3 [6-8]. Additionally, immune suppression induction, vascular mimicry, breast cancer stem cells, and metabolic escape may also be involved. p95HER2, a truncated form of HER2 that lacks the extracellular domain necessary for trastuzumab binding, is responsive to lapatinib, suggesting that pan-HER TKIs can effectively target such resistant forms by also acting on other receptors like EGFR that increase with trastuzumab exposure [37,38]. In the PICTURE study, pyrotinib plus capecitabine achieved a median PFS of 11.8 months (95% CI, 8.4 to 15.1) in HER2-positive advanced breast cancer patients with primary resistance to trastuzumab [39]. Further supporting this, the PANDORA study reported that pyrotinib plus docetaxel as a first-line treatment achieved a median PFS of 20.8 months in trastuzumab-pretreated patients compared to 14.8 months in trastuzumab-naïve patients [40]. Subgroup analysis in our study revealed a median PFS of 19.7 months in patients with primary resistance to trastuzumab compared to 10.9 months in the secondary resistant population (nominal p=0.207), supporting the mechanism of pan-HER TKIs in overcoming primary resistance to trastuzumab.

Several studies have highlighted the effectiveness of metronomic vinorelbine in metastatic breast cancer, with favorable median PFS of 7.4-12 months and DCR of 50%-88% [25,41-43]. One of the standout attributes of metronomic vinorelbine is its low incidence of severe toxicity, even during long-term use [25,41-43]. In our study, the highest grade of diarrhea observed without primary prophylaxis was grade 3, with an incidence of 27.8%. Comparatively, even with primary prophylaxis, grade 4 diarrhea was observed in the PHENIX and PHOEBE studies [10-12], with grade ≥ 3 diarrhea incidences were 30.8% and 30.5%, respectively, with the combination of pyrotinib and capecitabine; the PHILA and PHEDRA studies [13,14] reported even higher grade ≥ 3 diarrhea incidences of 46.5% and 44.4%, respectively, with pyrotinib combined with trastuzumab and docetaxel. Reduced incidence of severe diarrhea could improve patient compliance to pyrotinib administration. High-dose chemotherapy often leads to the selection of chemo-resistant tumor cell clones, as the cytotoxic stress preferentially eliminates drug-sensitive cells. Metronomic dosing mitigates this risk by maintaining constant pressure on the tumor environment, reducing the risk of drug resistance. Additionally, low-dose chemotherapy targets endothelial cells, enhancing the antiangiogenic effect. More frequent dosing schedules have been associated with the activation of antitumor immune responses, ultimately synergizing with other drugs to increase antitumor efficacy [25]. This may explain the numerically slightly higher median PFS observed in our study. The efficacy and feasibility of metronomic chemotherapy combined with targeted therapy has been demonstrated with promising results observed in several clinical trials combining metronomic chemotherapy with anti-HER2 agents and antiangiogenics [42,44-47].

Future directions in treatment may involve combining ADCs with small-molecule inhibitors, potentially offering even greater benefits to patients. The HER2CLIMB-02 trial has confirmed the efficacy advantages of combining ADCs with TKIs [48]. Additionally, ongoing studies like the Alliance A011801 trial, which investigates post-neoadjuvant T-DM1 with tucatinib/placebo in patients with residual HER2-positive invasive breast cancer [49], and the HER2CLIMB-04 trial, a phase 2 open-label trial of tucatinib plus T-DXd in patients with HER2 positive unresectable locally advanced or metastatic breast cancer with and without brain metastases [50], are expected to provide further insights into these promising combinations.

There are several limitations in this study. Given single-arm design and small sample size of this study, all results should be interpreted with caution. Due to limited availability of T-DM1, T-DXd and pertuzumab during the study period and economic factors, no patients in our study had been treated with these ADCs and pertuzumab, which is quite different from the patient characteristics of global population, impacting the extrapolation and it is also not easy to compare with other global studies. Nonetheless, this dual oral regimen appears to be a feasible approach in this setting and warrants further study in larger randomized trials. The mechanisms of pyrotinib and metronomic vinorelbine suggest potential synergies. Future research delving into tumor angiogenesis, immune markers, and cancer stem cell clusters could provide further insight into the biologic interactions between these agents. As we chart the path ahead, refining the dosage and regimen of this combination will be paramount. The incorporation of other targeted agents, immunotherapies, or antiangiogenics in a three-drug protocol might further amplify the treatment’s efficacy.

In summary, this study provides promising clinical evidence for dual oral pyrotinib and metronomic vinorelbine HER2-positive advanced breast cancer after trastuzumab failure. Further research will be instrumental in perfecting this combination and elucidating its optimal role in the treatment of such patients.

NOTES

Ethical Statement

The study was conducted in accordance with the Declarations of Helsinki and Good Clinical Practice and was approved by the ethics committee of Tianjin Medical University Cancer Institute and Hospital (approval number: E220691). Written informed consent was obtained from each patient. The study was registered with ClinicalTrials.gov, NCT04903652.

Author Contributions

Conceived and designed the analysis: Hao C, Wang X.

Collected the data: Shi Y, Tong Z, Li S, Liu X, Zhang L.

Contributed data or analysis tools: Shi Y, Tong Z, Li S, Liu X, Zhang L (Lan Zhang).

Performed the analysis: Zhang J, Meng W, Zhang L (Li Zhang).

Wrote the paper: Zhang J, Meng W, Zhang L (Li Zhang).

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements

We would like to acknowledge the patients and their families, the study investigators, and the clinical site staff. We thank Xuwei Fu (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.) for her input in study design, data interpretation, and statistical support; and Yilan Wu (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd.) for medical writing assistance.

Fig. 1.

Kaplan-Meier curves of progression-free survival (PFS) for human epidermal growth factor receptor 2–positive advanced breast cancer patients. (A) PFS curve for entire cohort (n=36). (B) PFS for subgroups with or without lung metastasis (median, 14.3 vs. 7.6 months; nominal p=0.037). (C) PFS for subgroups primarily or secondarily resistant to trastuzumab (median, 19.7 vs. 10.9 months; nominal p=0.207). (D) PFS for subgroups previously treated with trastuzumab (median, 13.6 months) in advanced or early disease stages (median, 13.9 vs. 11.8 months). (E) PFS for subgroups with or without previous lapatinib treatment (median, 8.3 vs. 15.3 months; nominal p=0.008).

Table 1.

Baseline characteristics

Characteristic	No. (%) (n=36)
Age (yr), median (range)	54 (31-71)
Female sex	35 (97.2)
ECOG PS
0	9 (25.0)
1	27 (75.0)
Metastatic sites at screening
Lung	27 (75.0)
Liver	12 (33.3)
Bone	18 (50.0)
Brain	6 (16.7)
Skin, lymph nodes, and soft tissues	32 (88.9)
Previous trastuzumab treatment
EBC	5 (13.9)
ABC	23 (63.9)
Both	8 (22.2)
No. of metastatic sites at screening
1	3 (8.3)
2	10 (27.8)
3	7 (19.4)
4 and above	16 (44.4)
HR status
HR+	19 (52.8)
HR–	17 (47.2)
Trastuzumab resistance
Primary	9 (25.0)
Secondary	27 (75.0)
Previous lapatinib treatment	15 (41.7)
Previous lines of chemotherapy for metastatic setting
0	1 (2.8)
1	13 (36.1)
2	14 (38.9)
3	7 (19.4)
4	1 (2.8)

ABC, advanced breast cancer; EBC, early breast cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hormone receptor.

Table 2.

The post-hoc subgroup analysis

Subgroup	mPFS (mo)	Nominal p-value
Site of metastasis (yes vs. no)
Bone	10.9 vs. 15.0	0.383
Brain	6.0 vs. 13.9	0.079
Brain	13.5 vs. 13.6	0.897
Liver	12.6 vs. 13.5	0.837
Lung	14.2 vs. 7.6	0.037
No. of metastasis
1	7.4	0.263
2	20.9
3	10.9
4 and above	12
Trastuzumab resistance
Primary vs. secondary	19.7 vs. 10.9	0.207
HR status
HR+ vs. HR–	11.8 vs. 14.2	0.323
Previous trastuzumab treatment
ABC	13.9	0.919
EBC	11.8
Both	13.6
Previous lapatinib treatment
Yes vs. no	8.3 vs. 15.3	0.008

ABC, advanced breast cancer; EBC, early breast cancer; HR, hormone receptor; mPFS, median progression-free survival.

Table 3.

Summary of adverse events

Adverse event	All treated (n=36)
Adverse event	Any grade	Grade 3
Diarrhea	34 (94.4)	10 (27.8)
Nausea	29 (80.6)	-
Vomiting	27 (75.0)	3 (8.3)
Decreased appetite	32 (88.9)	-
Stomachache	10 (27.8)	2 (5.6)
Neutropenia	14 (38.9)	1 (2.8)
Leucopenia	12 (33.3)	-
Anemia	11 (30.6)	1 (2.8)
Alanine aminotransferase increased	3 (8.3)	-
Aspartate aminotransferase increased	3 (8.3)	-

Values are presented as number (%). No grade 4/5 adverse events were reported.

REFERENCES

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12. Article PubMed
2. Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med. 2021;18:900–9. Article PubMed PMC
3. National Comprehensive Cancer Network. Breast cancer (version 4.2024) [Internet]. National Comprehensive Cancer Network; 2024 [cited 2024 Jul 10]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
4. Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22:525–31. Article PubMed
5. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat. 2009;118:113–24. Article PubMed PDF
6. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65:11118–28. Article PubMed PDF
7. Krop IE, Flores L, Najita JS, Mayer IA, Hobday TJ, Falkson CI, et al. The role of EGFR amplification in trastuzumab resistance: a correlative analysis of TBCRC003. J Clin Oncol. 2011;29(15 Suppl):528.Article
8. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878–87. Article PubMed PDF
9. Blair HA. Pyrotinib: first global approval. Drugs. 2018;78:1751–5. Article PubMed PDF
10. Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:351–60. Article PubMed
11. Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Abstract GS3-02: updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer. Cancer Res. 2022;82(4 Suppl):GS3–02. Article PDF
12. Yan M, Bian L, Hu X, Zhang Q, Ouyang Q, Feng J, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Transl Breast Cancer Res. 2020;1:13.Article
13. Song GH, Li HP, Di LJ, Yan Y, Jiang HF, Xu L, et al. Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice. Beijing Da Xue Xue Bao Yi Xue Ban. 2020;52:254–60. PubMed PMC
14. Chen Q, Ouyang D, Anwar M, Xie N, Wang S, Fan P, et al. Effectiveness and safety of pyrotinib, and association of biomarker with progression-free survival in patients with HER2-positive metastatic breast cancer: a real-world, multicentre analysis. Front Oncol. 2020;10:811.Article PubMed PMC
15. Le Du F, Dieras V, Curigliano G. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. Eur J Cancer. 2021;154:175–89. PubMed
16. Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383:e076065Article PubMed PMC
17. Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022;20:498.Article PubMed PMC PDF
18. Leveque D, Jehl F, Quoix E, Monteil H. Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. Xenobiotica. 1993;23:1325–33. Article PubMed
19. Sim SH, Park IH, Jung KH, Kim SB, Ahn JH, Lee KH, et al. Randomised phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). Br J Cancer. 2019;121:985–90. Article PubMed PMC PDF
20. Xie Y, Li Y, Ting L, Sang D, Yuan P, Li W, et al. Pyrotinib plus vinorelbine versus lapatinib plus capecitabine in patients with previously treated HER2-positive metastatic breast cancer: a multicenter, retrospective study. Front Oncol. 2021;11:699333.Article PubMed PMC
21. Li Y, Qiu Y, Li H, Luo T, Li W, Wang H, et al. Pyrotinib combined with vinorelbine in HER2-positive metastatic breast cancer: a multicenter retrospective study. Front Oncol. 2021;11:664429.Article PubMed PMC
22. Jiang K, Hong R, Xia W, Lu Q, Li L, Huang J, et al. Pyrotinib combined with vinorelbine in patients with previously treated HER2-positive metastatic breast cancer: a multicenter, single-arm, prospective study. Cancer Res Treat. 2024;56:513–21. Article PubMed PDF
23. Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010;10:301–6. Article PubMed
24. De Iuliis F, Salerno G, Taglieri L, Lanza R, Scarpa S. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori. 2015;101:30–5. Article PubMed PDF
25. Cazzaniga ME, Dionisio MR, Riva F. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett. 2017;400:252–8. Article PubMed
26. Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;68:1119–24. Article PubMed PDF
27. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91. Article PubMed PMC
28. Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C, et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER2(+) metastatic breast cancer. Oncologist. 2011;16:1535–46. Article PubMed PMC PDF
29. Makhlin I, DeMichele A. Trastuzumab deruxtecan: an antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep Med. 2022;3:100668.Article PubMed PMC
30. Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95. Article PubMed
31. Gourd E. Pyrotinib shows activity in metastatic breast cancer. Lancet Oncol. 2017;18:e643Article PubMed
32. Li Y, Tong Z, Wu X, Ouyang Q, Cai L, Li W, et al. Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): a nationwide, prospective, observational study. Int J Cancer. 2023;153:1809–18. PubMed
33. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res. 2010;16:4226–35. Article PubMed PDF
34. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Menard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer. 2006;13:221–32. Article PubMed
35. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011;29:166–73. Article PubMed
36. Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32:3212–20. Article PubMed
37. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99:628–38. Article PubMed
38. Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010;16:2688–95. Article PubMed PMC PDF
39. Cao J, Teng Y, Li H, Zhang L, Ouyang Q, Xie W, et al. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial. BMC Med. 2023;21:300.Article PubMed PMC PDF
40. Zheng Y, Cao WM, Shao X, Shi Y, Cai L, Chen W, et al. Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nat Commun. 2023;14:8314.Article PubMed PMC PDF
41. Liu CT, Hsieh MC, Su YL, Hung CM, Pei SN, Liao CK, et al. Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study. J Cancer. 2021;12:5355–64. Article PubMed PMC
42. Wang Z, Liu J, Ma F, Wang J, Luo Y, Fan Y, et al. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial. Breast Cancer Res Treat. 2021;188:441–7. Article PubMed PMC PDF
43. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008;26:4899–905. Article PubMed
44. Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, et al. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer: a multicenter, randomized phase III trial. BMC Cancer. 2016;16:780.PubMed PMC
45. Sanna G, Pestrin M, Moretti E, Biagioni C, De Santo I, Gabellini S, et al. A dose-finding study of metronomic oral vinorelbine in combination with oral cyclophosphamide and bevacizumab in patients with advanced breast cancer. Clin Breast Cancer. 2021;21:e332–9. Article PubMed
46. Orlando L, Lorusso V, Giotta F, Di Maio M, Schiavone P, Fedele P, et al. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: a phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). Breast. 2020;53:18–22. Article PubMed PMC
47. Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018;19:323–36. Article PubMed
48. Hurvitz S, Loi S, O’Shaughnessy J, Okines A, Tolaney S, Sohn JH, et al. Abstract GS01-10: HER2CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. Cancer Res. 2024;84(9 Suppl):GS01–10. Article PDF
49. O’Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021;17:4665–76. Article PubMed PMC
50. Hamilton E, Carey L, Ramos J, Chen Y, Krop I. Abstract OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (trial in progress). Cancer Res. 2022;82(4 Suppl):OT1-13-01.Article PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal
Luca Roncati
Cancers.2025; 17(8): 1323. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study

Cancer Res Treat. 2025;57(2):434-442. Published online August 9, 2024

DOI: https://doi.org/10.4143/crt.2024.340

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study

Fig. 1. Kaplan-Meier curves of progression-free survival (PFS) for human epidermal growth factor receptor 2–positive advanced breast cancer patients. (A) PFS curve for entire cohort (n=36). (B) PFS for subgroups with or without lung metastasis (median, 14.3 vs. 7.6 months; nominal p=0.037). (C) PFS for subgroups primarily or secondarily resistant to trastuzumab (median, 19.7 vs. 10.9 months; nominal p=0.207). (D) PFS for subgroups previously treated with trastuzumab (median, 13.6 months) in advanced or early disease stages (median, 13.9 vs. 11.8 months). (E) PFS for subgroups with or without previous lapatinib treatment (median, 8.3 vs. 15.3 months; nominal p=0.008).

Fig. 1.

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study

Characteristic	No. (%) (n=36)
Age (yr), median (range)	54 (31-71)
Female sex	35 (97.2)
ECOG PS
0	9 (25.0)
1	27 (75.0)
Metastatic sites at screening
Lung	27 (75.0)
Liver	12 (33.3)
Bone	18 (50.0)
Brain	6 (16.7)
Skin, lymph nodes, and soft tissues	32 (88.9)
Previous trastuzumab treatment
EBC	5 (13.9)
ABC	23 (63.9)
Both	8 (22.2)
No. of metastatic sites at screening
1	3 (8.3)
2	10 (27.8)
3	7 (19.4)
4 and above	16 (44.4)
HR status
HR+	19 (52.8)
HR–	17 (47.2)
Trastuzumab resistance
Primary	9 (25.0)
Secondary	27 (75.0)
Previous lapatinib treatment	15 (41.7)
Previous lines of chemotherapy for metastatic setting
0	1 (2.8)
1	13 (36.1)
2	14 (38.9)
3	7 (19.4)
4	1 (2.8)

Subgroup	mPFS (mo)	Nominal p-value
Site of metastasis (yes vs. no)
Bone	10.9 vs. 15.0	0.383
Brain	6.0 vs. 13.9	0.079
Brain	13.5 vs. 13.6	0.897
Liver	12.6 vs. 13.5	0.837
Lung	14.2 vs. 7.6	0.037
No. of metastasis
1	7.4	0.263
2	20.9
3	10.9
4 and above	12
Trastuzumab resistance
Primary vs. secondary	19.7 vs. 10.9	0.207
HR status
HR+ vs. HR–	11.8 vs. 14.2	0.323
Previous trastuzumab treatment
ABC	13.9	0.919
EBC	11.8
Both	13.6
Previous lapatinib treatment
Yes vs. no	8.3 vs. 15.3	0.008

Adverse event	All treated (n=36)
Adverse event	Any grade	Grade 3
Diarrhea	34 (94.4)	10 (27.8)
Nausea	29 (80.6)	-
Vomiting	27 (75.0)	3 (8.3)
Decreased appetite	32 (88.9)	-
Stomachache	10 (27.8)	2 (5.6)
Neutropenia	14 (38.9)	1 (2.8)
Leucopenia	12 (33.3)	-
Anemia	11 (30.6)	1 (2.8)
Alanine aminotransferase increased	3 (8.3)	-
Aspartate aminotransferase increased	3 (8.3)	-

Table 1. Baseline characteristics

ABC, advanced breast cancer; EBC, early breast cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hormone receptor.

Table 2. The post-hoc subgroup analysis

ABC, advanced breast cancer; EBC, early breast cancer; HR, hormone receptor; mPFS, median progression-free survival.